2. Signaling Pathways
  3. Epigenetics
  4. Protein Arginine Deiminase
  5. Protein Arginine Deiminase Inhibitor

Protein Arginine Deiminase Inhibitor

Protein Arginine Deiminase Inhibitors (21):

Cat. No. Product Name Effect Purity
  • HY-100514
    GSK484 hydrochloride
    		Inhibitor 99.72%
    GSK484 hydrochloride is a selective and reversible peptidylarginine deiminase 4 (PAD4) inhibitor. GSK484 hydrochloride demonstrates high affinity binding to PAD4 with IC50s of 50 nM in the absence of Calcium. In the presence of 2 mM Calcium, notably lower potency (250 nM) is observed.
  • HY-111347A
    BB-Cl-Amidine hydrochloride
    		Inhibitor 99.78%
    BB-Cl-Amidine hydrochloride is a peptidylarginine deminase (PAD) inhibitor.
  • HY-125099A
    AFM-30a hydrochloride
    		Inhibitor 99.96%
    AFM-30a hydrochloride is a potent protein arginine deiminase 2 (PAD2) inhibitor and has excellent PAD2-selectivity. AFM-30a hydrochloride binds to PAD2 with an EC50 value of 9.5 μM. AFM-30a hydrochloride also inhibits H3 citrullination with an EC50 value of 0.4 μM. AFM-30a hydrochloride can be used for the research of certain cancers and a variety of autoimmune diseases including rheumatoid arthritis (RA), multiple sclerosis, lupus, and ulcerative colitis.
  • HY-136557A
    AFM32a hydrochloride
    		Inhibitor 99.71%
    AFM32a (PAD2-IN-1) hydrochloride, a benzimidazole-based derivative, is a potent and selective protein arginine deiminase 2 (PAD2) inhibitor. AFM32a hydrochloride shows superior selectivity for PAD2 over PAD4 (95-fold) and PAD3 (79-fold).
  • HY-100574D
    D-Cl-amidine hydrochloride
    		Inhibitor 99.40%
    D-Cl-amidine hydrochloride is a potent and highly selective PAD1 inhibitor. D-Cl-amidine is well-torelated with no significant toxicity.
  • HY-126560A
    F-Amidine TFA
    		Inhibitor
    F-Amidine TFA is a Protein arginine deiminase 4 (PAD4) inhibitor. F-Amidine TFA can be used in the study of inflammatory and immune system diseases (such as rheumatoid arthritis).
  • HY-137655A
    BMS-P5 free base
    		Inhibitor 99.96%
    BMS-P5 free base is a specific and orally active peptidylarginine deiminase 4 (PAD4) inhibitor. BMS-P5 free base blocks MM-induced NET formation and delays progression of MM in a syngeneic mouse model.
  • HY-103058
    GSK199
    		Inhibitor 99.86%
    GSK199 is an orally active, reversible, and selective PAD4 inhibitor with an IC50 of 200 nM in the absence of calcium. GSK199 can be used for the research of rheumatoid arthritis.
  • HY-124586
    Streptonigrin
    		Inhibitor ≥99.0%
    Streptonigrin (Bruneomycin), a natural product produced by Streptomyces flocculus, possesses both anti-tumor and anti-bacterial activity. Streptonigrin acts as a pan-PAD inhibitor with IC50s of 48.3±34.2 µM, 26.1±0.3 µM, 0.43±0.03 µM, and 2.5±0.4 µM for PAD1, PAD2, PAD3, and PAD4, respectively.
  • HY-135304
    PAD-IN-2
    		Inhibitor 99.02%
    PAD-IN-2 is a potent pad4 inhibitor (IC50: <1 μM). PAD-IN-2 can be used in the research of auto-immune diseases and cancers, such as rheumatoid arthritis, vasculitis, systemic lupus erythematosis, cutaneous lupus erythematosis, ulcerative colitis, cystic fibrosis, asthma, multiple sclerosis and psoriasis.
  • HY-153450
    JBI-589
    		Inhibitor 98.93%
    JBI-589 is a non-covalent PAD4 isoform-selective inhibitor. JBI-589 reduces CXCR2 expression and blocks neutrophil chemotaxis. JBI-589 reduces primary tumor and metastases, and enhances the anti-tumor effect of checkpoint inhibitors.
  • HY-117777
    GSK121
    		Inhibitor 99.81%
    GSK-121 Trifluoroacetates a selective PAD4 inhibitor.
  • HY-120343
    GSK106
    		Inhibitor 98.00%
    GSK106 is an inactive control for the selective PAD4 inhibitors, GSK484 and GSK199.
  • HY-111347
    BB-Cl-Amidine
    		Inhibitor
    BB-Cl-Amidine is a peptidylarginine deminase (PAD) inhibitor.
  • HY-125099
    AFM-30a
    		Inhibitor
    AFM-30a is a potent protein arginine deiminase 2 (PAD2) inhibitor and has excellent PAD2-selectivity. AFM-30a binds to PAD2 with an EC50 value of 9.5 μM. AFM-30a also inhibits H3 citrullination with an EC50 value of 0.4 μM. AFM-30a can be used for the research of certain cancers and a variety of autoimmune diseases including rheumatoid arthritis (RA), multiple sclerosis, lupus, and ulcerative colitis.
  • HY-136557
    AFM32a
    		Inhibitor
    AFM32a (PAD2-IN-1), a benzimidazole-based derivative, is a potent and selective protein arginine deiminase 2 (PAD2) inhibitor. AFM32a shows superior selectivity for PAD2 over PAD4 (95-fold) and PAD3 (79-fold).
  • HY-155052
    PAD4-IN-2
    		Inhibitor
    PAD4-IN-2 (compound 5i) is a PAD4 inhibitor (IC50=1.94 μM). PAD4-IN-2 inhibits tumor growth in mice by specifically inhibiting the PAD4-H3cit-NETs pathway in neutrophils.
  • HY-100574C
    D-Cl-amidine
    		Inhibitor
    D-Cl-amidine is a potent and highly selective PAD1 inhibitor. D-Cl-amidine is well-torelated with no significant toxicity.
  • HY-100574B
    Cl-amidine TFA
    		Inhibitor
    Cl-amidine TFA is an orally active peptidylarginine deminase (PAD) inhibitor, with IC50 values of 0.8 μM, 6.2 μM and 5.9 μM for PAD1, PAD3, and PAD4, respectively. Cl-amidine TFA induces apoptosis in cancer cells. Cl-amidine TFA induces microRNA (miR)-16 (miRNA-16, microRNA-16) expression and causes cell cycle arrest. Cl-Amidine TFA prevents histone 3 citrullination and neutrophil extracellular trap formation, and improves survival in a murine sepsis model.
  • HY-137655
    BMS-P5
    		Inhibitor
    BMS-P5 is a specific and orally active peptidylarginine deiminase 4 (PAD4) inhibitor. BMS-P5 blocks MM-induced NET formation and delays progression of MM in a syngeneic mouse model.